Article

BMD-erosions correlation in RA: Potential for bone-directed treatments?

Hip bone mineral density (BMD) correlates with erosion scores in postmenopausal women who have rheumatoid arthritis (RA), although the relationship is not statistically significant after adjustment for clinical factors. BMD and erosions appear to be more strongly correlated in patients with early RA. Solomon and coworkers studied 163 postmenopausal women being treated for RA but not for osteoporosis.

Hip bone mineral density (BMD) correlates with erosion scores in postmenopausal women who have rheumatoid arthritis (RA), although the relationship is not statistically significant after adjustment for clinical factors. BMD and erosions appear to be more strongly correlated in patients with early RA.

Solomon and coworkers studied 163 postmenopausal women being treated for RA but not for osteoporosis. Study participants underwent dual-energy x-ray absorptiometry of the hip and spine, as well as hand radiographs, and they completed a questionnaire.

The erosion score correlated significantly with total hip BMD but not with spine BMD. Study participants who were positive for rheumatoid factor (RF) (63%) had significantly lower hip BMD than those who were RF negative; however, spine BMD appeared to bear no relationship to RF status. After controlling for variables (eg, age, body mass index, and cumulative dose of oral corticosteroids), the relationship between BMD and focal erosions vanished.

The authors noted that an association between erosions and BMD may be most relevant for patients with severe or early unmanaged RA and that recognizing it probably will increase in importance as more bone-directed treatments become part of RA management (eg, managing multiple skeletal manifestations of RA with a single agent).

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.